# Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Canonical URL: https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investigator-sponsored-trial-of-seres-ser-155-in-immune-checkpoint-inhibitor-related-enterocolitis
Ticker: MCRB
Company: Seres Therapeutics
Source: Seres Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.serestherapeutics.com
## Summary

CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune

## Article Body
CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) evaluating SER-155 in patients with immune
## Recent Company News
- 2026-06-25 13:46 EST — [Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-host-webcast-on-july-8-2026-to-discuss-results-of-investigator-sponsored-trial-of-seres-ser-155-in-immune-checkpoint-inhibitor-related-enterocolitis) — Source: Seres Therapeutics
- 2026-06-25 13:46 EST — [Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-two-transactions-to-strengthen-balance-sheet-reduce-on-going-lease-costs-and-extend-projected-operating-cash-runway-well-into-the-first-quarter-of-2027) — Source: Seres Therapeutics
- 2026-06-25 13:46 EST — [Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-h-c-wainwright-4th-annual-bioconnect-investor-conference) — Source: Seres Therapeutics
- 2026-06-25 13:46 EST — [Seres Therapeutics to Participate in Piper Sandler Healthcare Conference](https://biopharmsignal.com/news/MCRB/seres-therapeutics-to-participate-in-piper-sandler-healthcare-conference) — Source: Seres Therapeutics
- 2026-06-25 13:46 EST — [Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy](https://biopharmsignal.com/news/MCRB/seres-therapeutics-announces-publications-in-nature-medicine-and-journal-of-infectious-diseases-highlighting-vowsttm-mechanism-of-action-and-supporting-broader-live-biotherapeutic-strategy) — Source: Seres Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)